Publications by authors named "P Grimbert"
Introduction: Membranous nephropathy can lead to end-stage kidney disease, for which kidney transplantation is the preferred therapy. However, the disease often relapses, which can impact allograft survival.
Methods: We conducted a prospective multicenter study in France involving 72 patients with membranous nephropathy who were awaiting and then underwent kidney transplantation.
Article Synopsis
- The study assesses the safety and efficacy of the anti-CD38 monoclonal antibody daratumumab for kidney transplant candidates with high panel reactive antibodies.
- In the trial, 23 patients were involved across two phases, with notable mild infusion-related adverse events but no serious complications.
- Results showed significant, temporary reductions in anti-HLA antibodies at 3 months, but most immune markers returned to baseline levels after 12 months, indicating less than 40% of patients had a lasting positive response.
High human leukocyte antigen (HLA) sensitization limits access to compatible transplantation. New CD38-targeting agents have been shown to reduce anti-HLA antibodies, although with important interpatient variability. Thus, pretreatment identification of responder and nonresponder (NR) patients is needed for treatment decision-making.
View Article and Find Full Text PDFOnce-daily extended-release tacrolimus (LCPT) exhibits increased bioavailability versus immediate-release (IR-TAC) and prolonged release (PR-TAC) tacrolimus. Improvements in tremor were previously reported in a limited number of kidney transplant patients who switched to LCPT. We conducted a non-interventional, non-randomized, uncontrolled, longitudinal, prospective, multicenter study to assess the impact of switching to LCPT on tremor and quality of life (QoL) in a larger population of stable kidney transplant patients.
View Article and Find Full Text PDFLate opportunistic infections (OI) occurring beyond the first year after kidney transplantation (KT) are poorly described and not targeted by prophylactic strategies. We performed a ten-year retrospective monocentric cohort study describing epidemiology, risk factors and impact of late OI occurring 1 year after KT. We included clinically symptomatic OI requiring treatment besides BK virus nephropathy.
View Article and Find Full Text PDF